FSD Pharma Inc. (NASDAQ:HUGE) Short Interest Update

FSD Pharma Inc. (NASDAQ:HUGE) saw a large decrease in short interest in June. As of June 15th, there was short interest totalling 121,800 shares, a decrease of 58.3% from the May 31st total of 292,100 shares. Based on an average daily volume of 488,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.4% of the company’s stock are short sold.

FSD Pharma Stock Performance

NASDAQ HUGE traded down $0.01 on Friday, reaching $0.16. The stock had a trading volume of 27,645,139 shares, compared to its average volume of 730,048. The firm has a fifty day moving average of $0.31 and a two-hundred day moving average of $0.64. FSD Pharma has a 1-year low of $0.15 and a 1-year high of $1.68.

FSD Pharma (NASDAQ:HUGE) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). On average, equities analysts forecast that FSD Pharma will post -0.22 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Singular Research reissued a “buy-venture” rating on shares of FSD Pharma in a report on Tuesday, May 7th.

Institutional Trading of FSD Pharma

A hedge fund recently bought a new stake in FSD Pharma stock. Scotia Capital Inc. acquired a new position in shares of FSD Pharma Inc. (NASDAQ:HUGE) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,273 shares of the company’s stock, valued at approximately $55,000. Scotia Capital Inc. owned about 0.16% of FSD Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 1.24% of the company’s stock.

FSD Pharma Company Profile

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.